Physician profile
David J James
NPI 1205093846
$10,850.09
in general payments reported to CMS, 2019-2025
45 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $801 · 2021: $2,016 · 2022: $1,924 · 2023: $1,344 · 2024: $1,742 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,939.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,232.93 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,015.95 | 2019-2025 | |
| Boston Scientific Corporation | $896.74 | 2019-2025 | Watchman Flx, Watchman, Opticross |
| Astrazeneca Pharmaceuticals LP | $780.58 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $604.44 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $551.44 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $490.27 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $473.10 | 2019-2025 | Lifevest |
| Amgen INC. | $459.13 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $404.05 | 2019-2024 | |
| Medtronic, INC. | $365.63 | 2021-2024 | Onyx Frontier, Corevalve Evolut R |
| Pfizer INC. | $308.00 | 2019-2025 | |
| Esperion Therapeutics, INC. | $282.02 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $280.89 | 2020-2022 | |
| Heartflow, INC. | $271.62 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $259.98 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $232.18 | 2019-2025 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $214.20 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $204.17 | 2025 | Onpattro |
| Abbott Laboratories | $200.77 | 2020-2024 | Jot Dx, Cardiomems, Ensite |
| Lexicon Pharmaceuticals, INC. | $151.02 | 2023-2024 | Inpefa |
| Arbor Pharmaceuticals, INC. | $126.85 | 2020-2022 | |
| Edwards Lifesciences Corporation | $126.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.95 | 2022-2025 | |
| Bridgebio Pharma, INC. | $95.00 | 2025 | Attruby |
| Cardiva Medical, INC. | $90.89 | 2021-2024 | Optowire |
| Lilly USA, LLC | $83.61 | 2020-2025 | Mounjaro, Zepbound |
| Scpharmaceuticals INC. | $78.46 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $57.60 | 2020-2021 | |
| Cvrx, INC. | $51.77 | 2024-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $49.45 | 2024 | Arcalyst |
| Philips North America LLC | $37.58 | 2023 | |
| Impulse Dynamics (USA) INC. | $33.29 | 2022-2024 | Optimizer |
| Chiesi USA, INC. | $28.97 | 2021-2022 | |
| Lundbeck LLC | $28.62 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $26.09 | 2019-2021 | |
| Penumbra, INC. | $24.86 | 2022 | |
| Atricure, INC. | $22.95 | 2024 | |
| Angiodynamics, INC. | $17.02 | 2023 | Auryon Laser System 100-120 Vac |
| Althera Pharmaceuticals LLC | $16.27 | 2022 | |
| W. L. Gore & Associates, INC. | $15.61 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $13.92 | 2023 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $13.86 | 2023 | Edarbyclor |
| Acarix USA INC. | $10.13 | 2023 | Cadscor System |
| Bardy Diagnostics, INC. | $5.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.